What type of drug does Alpelisib belong to? Is it a targeted drug?

Alpelisib (Alpelisib) is a new type of targeted drug that belongs to the class of PI3K (phosphatidylinositol 3-kinase) inhibitor drugs. It blocks the growth, proliferation and survival signals of cancer cells by selectively inhibiting the p110α isoform in the PI3K signaling pathway, and has significant efficacy in the treatment of breast cancer patients carrying PIK3CA mutations. This mechanism of action makes Apelvis an important player in the field of precision therapy, especially for patients with hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutations.

In clinical treatment, apelvis is usually used in combination with the aromatase inhibitor fulvestrant, and is suitable for patients with advanced breast cancer who have previously received endocrine therapy but have developed resistance. Studies have shown that this combination regimen can significantly extend the progression-free survival of patients, especially in patients with PIK3CA mutations. Therefore, doctors will conduct genetic testing before taking the drug to confirm whether it is suitable to use Apelvis.

As a targeted drug, Apelvis is also associated with some specific adverse reactions, among which hyperglycemia is one of the most common problems. Patients with diabetes or glucose metabolism problems need special attention. In addition, it may cause side effects such as rash, diarrhea, weight loss, and decreased appetite. Therefore, blood sugar and other body indicators need to be closely monitored during use, and the treatment plan needs to be adjusted if necessary.

Overall, Apelvis is a precision targeted therapy drug, and its development and application mark that breast cancer treatment has entered a new era of molecular classification and personalized medication. It not only improves the treatment options for patients with advanced breast cancer, but also provides a new idea for the treatment of gene-driven tumors. However, patients need to carefully manage related risks under the guidance of professional doctors during use.

Reference materials:https://www.drugs.com/